2008
DOI: 10.1016/j.vaccine.2008.04.076
|View full text |Cite
|
Sign up to set email alerts
|

Long-term stability of Vero cell-derived inactivated Japanese encephalitis vaccine prepared using serum-free medium

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
21
0

Year Published

2009
2009
2018
2018

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 25 publications
(22 citation statements)
references
References 18 publications
1
21
0
Order By: Relevance
“…Vaccines were formulated and administered to mice as previously described (11). JE-ADVAX was a formulation of Vero cell culture-grown, inactivated JE vaccine (ccJE; Beijing-1 strain) (9) together with Advax adjuvant (Vaxine Pty. Ltd., Adelaide, Australia) comprising delta inulin by itself or in a formulation further containing a CpG oligonucleotide (Advax-2).…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Vaccines were formulated and administered to mice as previously described (11). JE-ADVAX was a formulation of Vero cell culture-grown, inactivated JE vaccine (ccJE; Beijing-1 strain) (9) together with Advax adjuvant (Vaxine Pty. Ltd., Adelaide, Australia) comprising delta inulin by itself or in a formulation further containing a CpG oligonucleotide (Advax-2).…”
Section: Methodsmentioning
confidence: 99%
“…However, JE-VAX remains the "gold standard" for immunogenicity and safety comparisons of new-generation vaccines against JE (8). Using JE-VAX as a comparator, we showed that JE-ADVAX, a Vero cell culture-grown inactivated JEV antigen (ccJE) (9), combined with Advax, a novel polysaccharide adjuvant derived from delta inulin (10), provided immunogenicity greatly superior to that of JE-VAX in mice and horses (11). In the same study, we also found that JE-ADVAX elicited levels of neutralizing antibody against serologically related flaviviruses of medical significance (West Nile and Murray Valley encephalitis viruses) that were indicative of cross-protective immunity, because they exceeded the titers against the homologous virus (JEV) generated by immunization with the gold standard JE-VAX (11).…”
mentioning
confidence: 99%
“…Another contributor to the unique success of JE-ADVAX in inducing cross-protective WNV antibodies is likely the greater antigenicity of the ccJE antigen compared to that of the earlier mouse brain-derived JE-VAX antigen (28). This likely relates to the less harsh formalin inactivation step used for production of the ccJE antigen (28), which may prevent damage to critical epitopes on the JEV E protein needed for induction of cross-protective neutralizing antibodies. In support of this possibility, two doses of ccJE antigen even without adjuvant induced low titers of cross-neutralizing antibodies and provided partial protection against WNV.…”
Section: Cd8mentioning
confidence: 99%
“…In preclinical models, Advax was shown to enhance the immunogenicity of a broad range of viral vaccines, including pandemic influenza virus (23), HIV (24), hepatitis B virus (25), African horse sickness virus (26), and JEV (18,27). JE-ADVAX is a recently developed JEV vaccine based on the combination of Advax adjuvant with a Vero cellderived, formalin-inactivated JEV antigen (28). JE-ADVAX was shown in a previously published study (18) to provide immunogenicity against JEV superior to that provided by either the older mouse brain JE-VAX vaccine, an inactivated cell culture JEV vaccine adjuvanted with aluminum hydroxide (JESPECT; Novartis) (29), or a live attenuated chimeric yellow fever virus-JEV vaccine recently licensed in Australia and Thailand (Chimerivax-JE; Sanofi-Pasteur).…”
mentioning
confidence: 99%
“…7 New inactivated JE vaccines produced in Vero cells have been licensed or are in development. 8,9 A live attenuated virus grown in primary hamster kidney cells, manufactured in China (Chengdu Biological Products Institute, People's Republic of China), was licensed in 1988 and has only recently been made available in Asian countries outside China; this vaccine is recommended in some countries as a one dose in a primary immunization schedule followed by booster dose administration.…”
Section: Introductionmentioning
confidence: 99%